Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
letter
. 2005 Mar;64(3):509–510. doi: 10.1136/ard.2004.021378

Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab

F Broussais, M Kawashima, H Marotte, P Miossec
PMCID: PMC1755413  PMID: 15708911

Full Text

The Full Text of this article is available as a PDF (63.1 KB).

Figure 1.

Figure 1

 Clinical course and main biological variables for TB and CML diagnosis. (A) The course of the platelet count during infliximab infusions and treatment against CML. (B) Body weight is shown. (C) Kinetics of the bcr-abl transcript expression.

Figure 2.

Figure 2

 Th1 immune defect in this and other patients with RA. PBMC from the patient, control patients with RA (n = 15), and healthy controls (n = 14) were stimulated with or without 1 ng/ml of IL12 or a combination of IL12 (1 ng/ml) and IL18 (5 ng/ml). IFNγ concentrations in the culture supernatants were measured by an enzyme linked immunosorbent assay (ELISA). p Values compare controls and patients with RA.


Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES